Levobunolol hydrochloride (BioDeep_00000678364)

   


代谢物信息卡片


Levobunolol hydrochloride

化学式: C17H26ClNO3 (327.1601)
中文名称: 盐酸左布诺洛尔
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O.Cl
InChI: /m0./s1

描述信息

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent
Levobunolol (l-Bunolol) hydrochloride is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol hydrochloride is an ocular hypotensive agent and lowers mean intraocular pressure (IOP). Levobunolol hydrochloride can be used for glaucoma and superior oblique myokymia (SOM) research[1][2][3].

同义名列表

3 个代谢物同义名

Levobunolol hydrochloride; l-Bunolol hydrochloride; Levobunolol (hydrochloride)



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Y Imamura, T Koga, T Higuchi, M Otagiri, E Sugino, S Hibino. Inhibitory effect of drugs with a ketone group on reduction of acetohexamide catalyzed by carbonyl reductase from rabbit kidney. Journal of enzyme inhibition. 1997 Feb; 11(4):285-92. doi: 10.3109/14756369709027657. [PMID: 9208371]
  • F Li, S F Cooper, M Côté, C Ayotte. Determination of the enantiomers of bunolol in human urine by high-performance liquid chromatography on a chiral AGP stationary phase and identification of their metabolites by gas chromatography-mass spectrometry. Journal of chromatography. B, Biomedical applications. 1994 Oct; 660(2):327-39. doi: 10.1016/0378-4347(94)00295-9. [PMID: 7866523]
  • A Harris, V Malinovsky, B Martin. Correlates of acute exercise-induced ocular hypotension. Investigative ophthalmology & visual science. 1994 Oct; 35(11):3852-7. doi: NULL. [PMID: 7928182]
  • Y H Lee, U B Kompella, V H Lee. Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit. Experimental eye research. 1993 Sep; 57(3):341-9. doi: 10.1006/exer.1993.1133. [PMID: 7901046]
  • C C Chen, J Anderson, M Shackleton, J Attard. The disposition of bunolol in the rabbit eye. Journal of ocular pharmacology. 1987; 3(2):149-57. doi: 10.1089/jop.1987.3.149. [PMID: 3332677]
  • G D Novack, D D Tang-Liu, E P Kelley, S S Liu, C D Shen, E Duzman. Plasma levobunolol levels following topical administration with reference to systemic side effects. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 1987; 194(4):194-200. doi: 10.1159/000309765. [PMID: 3306546]
  • M J Antonaccio, J High, J M DeForrest, E Sybertz. Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function. The Journal of pharmacology and experimental therapeutics. 1986 Jul; 238(1):378-87. doi: . [PMID: 2873238]
  • H Hengy, E U Kölle. Determination of levobunolol and dihydrolevobunolol in blood and urine by high-performance liquid chromatography using fluorescence detection. Journal of chromatography. 1985 Mar; 338(2):444-9. doi: 10.1016/0378-4347(85)80119-5. [PMID: 3889026]
  • F J Leinweber, R C Greenough, F J Di Carlo. Bunolol metabolism by dogs: urinary excretion of 5-hydroxytetralone. Xenobiotica; the fate of foreign compounds in biological systems. 1978 Apr; 8(4):239-43. doi: 10.3109/00498257809056145. [PMID: 347724]
  • F J Leinweber, J M Szpiech, F J Di Carlo. l-bunolol metabolites in human urine. Pharmacology. 1978; 16(2):70-7. doi: 10.1159/000136749. [PMID: 339235]
  • F J Leinweber, J M Szpiech, F J Di Carlo. l-Bunolol metabolism in rats: identification of urinary metabolites. Journal of pharmaceutical sciences. 1978 Jan; 67(1):129-31. doi: 10.1002/jps.2600670138. [PMID: 338886]
  • F J Di Carlo, F J Leinweber, J M Szpiech, I W Davidson. Metabolism of l-bunolol. Clinical pharmacology and therapeutics. 1977 Dec; 22(6):858-63. doi: 10.1002/cpt1977226858. [PMID: 336256]
  • F J Leinweber, R C Greenough, F J Di Carlo. Bunolol metabolism by dogs: identification of basic metabolites and their conjugates. Journal of pharmaceutical sciences. 1977 Nov; 66(11):1570-5. doi: 10.1002/jps.2600661118. [PMID: 335043]
  • H Gavras, I Gavras, H R Brunner, J H Laragh. Effect of a new beta-adrenergic blocker, l-bunolol, on blood pressure and on the renin-aldosterone system. Journal of clinical pharmacology. 1977 May; 17(5-6):350-7. doi: 10.1002/j.1552-4604.1977.tb04615.x. [PMID: 323300]
  • S Morita, Y Irie, S Sakuragi, H Kori. [Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent. (6) Pharmacokinetics of carteolol in the rat, dog, rabbit and man]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1977 Mar; 73(2):229-35. doi: 10.1254/fpj.73.229. [PMID: 328355]
  • S Morita, Y Irie, Y Saitoh, H Kohri. Evaluation of a new beta-adrenergic blocking agent, carteolol, based on metabolic responses in rats-I. Blockade in vivo of epinephrine- and isoproterenol-induced alterations of blood concentrations of carbohydrate and lipid intermediary metabolites. Biochemical pharmacology. 1976 Aug; 25(16):1836-42. doi: 10.1016/0006-2952(76)90187-8. [PMID: 183783]
  • H Kohri, S Morita, K Nakagawa, H Nishino. [Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic agent. (3) Autoradiographic total body distribution studies in mice]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1976 Apr; 72(3):341-50. doi: 10.1254/fpj.72.341. [PMID: 9341]